Product
BI 836880
4 clinical trials
6 indications
Indication
Wet Macular DegenerationIndication
Non-squamousIndication
Lung CancerIndication
CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
MetastasisClinical trial
Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).Status: Completed, Estimated PCD: 2023-11-01
Clinical trial
An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-06
Clinical trial
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 (Ezabenlimab) Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyStatus: Active (not recruiting), Estimated PCD: 2024-06-28